arrow
C

Cristina R. Antonescu

Memorial Sloan Kettering Cancer Center
H指数:142
被引数:7.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrated Clinicopathologic and Multiomic Profiling Reveals MEIS1-Rearranged Sarcoma as a Distinct Entity With 2 Prognostic Subgroups

整合临床病理与多组学分析揭示MEIS1重排肉瘤为具有2个预后亚组的独立实体

2026-08-010
PRE
Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in MYOD1-mutant rhabdomyosarcoma

单细胞蛋白质活性分析揭示了MYOD1突变型横纹肌肉瘤中异常的肌发生以及IGF2-PI3K通路的依赖性。

2026-02-270
OA
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

在去分化脂肪肉瘤中序贯使用CDK4/6和PD-1抑制剂后的肿瘤与免疫动态变化:一项2期研究的结果

2026-02-010
PRE
PRRX1-rearranged Fibroblastic Tumors

PRRX1重排成纤维细胞肿瘤

2026-01-010
PRE
DNA Methylation Profiling Classifies and Reveals Origin of Gynecologic Central Nervous System-like Tumors

DNA甲基化谱分析对妇科类中枢神经系统肿瘤进行分类并揭示其起源

2025-11-220
PRE
Angiomatoid fibrous histiocytoma occurring at distal/acral extremity sites: clinicopathological and molecular study of 26 cases highlighting frequent myxoid histology and site-dependent genotypic variation

血管外皮瘤样纤维组织细胞瘤发生于远端/肢端部位:26例病例的临床病理及分子学研究,强调其常见的黏液样组织学特征和部位依赖性基因型变异

2025-08-010
OA
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma

一项关于CSF1R抑制剂vimseltinib与PD-L1抑制剂avelumab联合治疗晚期肉瘤的I期研究

2025-07-250
OAAI
Hyalinizing Clear Cell Carcinoma (HCCC) of the Head and Neck: A Multicenter Retrospective Study of 87 Cases Focusing on Prognostic Pathologic Features and Grading scheme

头颈部透明细胞癌(HCCC):一项聚焦于预后病理特征和分级方案的多中心回顾性研究(共87例)

2025-07-030
PRE